International Stem Cell Corp. (ISCO) Developing Therapeutic Products from Its Own Intellectual Property

As part of its quest to successfully develop stem cells for research and therapy, the International Stem Cell Corporation (OTCQB: ISCO) has been using a powerful new stem cell technology to address the problem of immune-rejection. Most recently, the Carlsbad, California-based company has been focused on utilizing parthenogenesis to advance the field of regenerative medicine.

Parthenogenesis is a process that uses unfertilized human eggs to create a new class of pluripotent human stem cells. These stem cells, known as human parthenogenetic stem cells (hpSCs), are specialized because they can be immune-matched to millions of people, and a small number of hpSC lines alone can provide enough immune-matched cells for a large fraction of the world’s population. HpSCs also have the added benefit of retaining many of the advantages usually linked to embryonic stem cells while circumventing the ethical issues.

By relying on its novel business model consisting of a number of revenue-generating subsidiaries, including Lifeline Cell Technology and Lifeline Skin Care, ISCO has been developing therapeutic products from its own intellectual property for years.

Thanks to the creation of the UniStemCell bank, the foundation of ISCO’s research and the globe’s greatest collection of non-embryonic histocompatible human stem cells used for research and commercial use, ISCO has been able to innovate in the area of therapeutics. The company, which is committed to developing stem cell treatments for neurological disorders, liver diseases and blindness caused by corneal damage, has been able to focus its hpSCs research efforts on treating these diseases and disorders, especially in areas where cellular replacement has been shown to be effective clinically, but there is a limited or no viable source of safe, ethical cells to treat patients.

At the same time, Lifeline Skin Care, a wholly-owned ISCO subsidiary and cosmeceutical business, has been developing, manufacturing and marketing cosmetic skin care products using a proprietary extract derived from the company’s pluripotent stem cells. Lifeline Cell Technology, another wholly-owned subsidiary and research products business, has also been creating, manufacturing and marketing human cell culture products, including frozen human “primary” cells and the reagents (media) needed to grow, maintain and differentiate the cells.

So not only has ISCO’s research and development team been using its hpSCs to make important breakthroughs in the treatment of a number of serious diseases, the company has also developed two successful business units which generate revenues from the sale of products that employ ISCO’s scientific discoveries.

For more information, visit www.internationalstemcell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net